STOCK TITAN

BioLineRx Ltd. (BLRX) SEC Filings, Jun-Jul 2025

BLRX NASDAQ

BioLineRx Ltd. filings document the regulatory record of a foreign private issuer focused on oncology and rare-disease drug development. Recent Form 6-K reports include financial results, interim consolidated financial statements, operating and financial reviews, and press-release exhibits incorporated by reference into effective Securities Act registration statements.

The filings also record company-specific matters such as the GLIX1 collaboration and joint-venture agreements with Hemispherian, GLIX1 patent and clinical-development disclosures, motixafortide and APHEXDA commercial context, and a final arbitration award involving the motixafortide in-licensing agreement. These disclosures frame BioLineRx's business updates, capital commitments, intellectual-property position, legal contingencies, and governance authorization as a Nasdaq- and TASE-listed issuer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
prospectus
-
Form 6-K
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
current report

FAQ

How many BioLineRx Ltd. (BLRX) SEC filings are available on StockTitan?

StockTitan tracks 42 SEC filings for BioLineRx Ltd. (BLRX), including 20-F annual reports and 6-K reports. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for BioLineRx Ltd. (BLRX)?

The most recent SEC filing for BioLineRx Ltd. (BLRX) was filed on November 18, 2026.